Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Langer-Gould Annette M, Smith Jessica B, Nielsen Allen Scott, Beaber Brandon E, Brara Sonu M, Amirova Samira, Su Elaine, Li Bonnie H, Z Esfahani Neda, Torres Fernando, Xu Stanley
Аннотация
BACKGROUND: Higher cumulative rituximab doses are associated with greater risks of infections. Therefore, we routinely extend low-dose rituximab (500 mg) intervals in people with relapsing multiple sclerosis (pwRMS) from every 6(q6mo) to 12 months(q12mo) to 18(q18mo) and/or 24 months(q24mo).
OBJECTIVE: To determine whether q18-24mo extension increases disease activity risks compared to continuing q6-12mo intervals.
METHODS: We conducted a retrospective cohort study of rituximab-treated pwRMS with no evidence of disease activity (absence of relapses, MRI disease activity and disability progression, NEDA-3, 96.6%) during the first year on rituximab.
RESULTS: We identified 1052 patients (mean age = 38.5 years; 71.5% female). 467 (44.4%) pwRMS received at least one q18-24mo 500 mg interval and 585 never extended beyond q6-12mo. Relapses and/or MRI disease activity (2.4%) and failing NEDA-3 (2.9%) were uncommon. Extending dosing to q18-24mo was not associated with an increased risk of failing NEDA-3 in inverse probability of treatment weighting propensity-score adjusted intention-to-treat (hazard ratio [HR] = 0.57, 95%CI = 0.21-1.57, p = 0.275) or per-protocol analyses (HR = 0.56, 95%CI = 0.17-1.86, p = 0.348) over 3-5 years of follow-up.
CONCLUSION: Extending low-dose rituximab after at least 1 year of clinical and radiological stability up to q24mo was not associated with an increased risk of disease activity compared to continuing q6-12mo intervals in this large, population-based cohort.
OBJECTIVE: To determine whether q18-24mo extension increases disease activity risks compared to continuing q6-12mo intervals.
METHODS: We conducted a retrospective cohort study of rituximab-treated pwRMS with no evidence of disease activity (absence of relapses, MRI disease activity and disability progression, NEDA-3, 96.6%) during the first year on rituximab.
RESULTS: We identified 1052 patients (mean age = 38.5 years; 71.5% female). 467 (44.4%) pwRMS received at least one q18-24mo 500 mg interval and 585 never extended beyond q6-12mo. Relapses and/or MRI disease activity (2.4%) and failing NEDA-3 (2.9%) were uncommon. Extending dosing to q18-24mo was not associated with an increased risk of failing NEDA-3 in inverse probability of treatment weighting propensity-score adjusted intention-to-treat (hazard ratio [HR] = 0.57, 95%CI = 0.21-1.57, p = 0.275) or per-protocol analyses (HR = 0.56, 95%CI = 0.17-1.86, p = 0.348) over 3-5 years of follow-up.
CONCLUSION: Extending low-dose rituximab after at least 1 year of clinical and radiological stability up to q24mo was not associated with an increased risk of disease activity compared to continuing q6-12mo intervals in this large, population-based cohort.